Review: Influence of the CYP450 Genetic Variation on the Treatment of Psychotic Disorders

Journal of Clinical Medicine

Ignacio Ramos-Gallego¹  María Isidoro-García²  Lorena Carrascal-Laso³  Manuel A. Franco-Martín³ 

[1] Departamento de Fisiología y Farmacología, Universidad de Salamanca, 37007 Salamanca, Spain;Farmacogenética y Medicina de Precisión, Servicio de Bioquímica, Hospital Universitario de Salamanca, IBSAL, 37007 Salamanca, Spain;Servicio de Psiquiatría, Hospital Provincial de Zamora, IBSAL, 49071 Zamora, Spain;

关键词: schizophrenia;    antipsychotics;    psychopharmacology;    genetics;    gene expression;   

DOI  :  10.3390/jcm10184275

来源: DOAJ

【 摘 要 】

Second-generation antipsychotic metabolism is mainly carried out by the CYP450 superfamily, which is highly polymorphic. Therefore, knowing the influence of the different known CYP450 polymorphisms on antipsychotic plasmatic levels and, consequently, the biological effect could contribute to a deeper knowledge of interindividual antipsychotic treatment variability, prompting possible solutions. Considering this, this state of the art review aimed to summarize the current knowledge about the influence of the diverse characterized phenotypes on the metabolism of the most used second-generation antipsychotics. Forty studies describing different single nucleotide polymorphisms (SNPs) associated with the genes CYP1A2, CYP2D6, CYP3A4, CYP3A5, and ABCB1 and their influence on pharmacokinetics of olanzapine, clozapine, aripiprazole, risperidone, and quetiapine. Most of the authors concluded that although significant differences in the pharmacokinetic parameters between the different phenotypes could be observed, more thorough studies describing pharmacokinetic interactions and environmental conditions, among other variables, are needed to fully comprehend these pharmacogenetic interactions.

【 授权许可】

Unknown